Patents by Inventor Maxime Ranger

Maxime Ranger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150057316
    Abstract: The present description relates to compounds of Formula I (A+ X?), a diastereoisomer, an enantiomer, or a mixture thereof, pharmaceutical composition comprising same and uses thereof for gastrointestinal endoscopic and medical imaging applications, and for the treatment of visceral pain: Where R1 and R2 are as defined herein
    Type: Application
    Filed: March 11, 2013
    Publication date: February 26, 2015
    Inventors: Jean-Francois Meunier, Cheuk Kun Lau, Daniel Guay, Gregory Bydlinski, Nadejda Spassova, Louis-David Cantin, Maxime Ranger
  • Patent number: 7838600
    Abstract: The instant invention provides a two-step polymerization process for preparing amphiphilic poly(N-vinyl-2-pyrrolidone), (PVP)-block-polyester copolymers and other diblock and triblock copolymers consisting of PVP as one block. The block copolymers of the invention can be used as vehicles for drug delivery.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: November 23, 2010
    Assignees: Labopharm, Inc., Labopharm Europe Limited, Labopharm (Barbados) Limited
    Inventors: Laibin Luo, David Lessard, Sandra Gori, Maxime Ranger, Yuan Wang, Julie Lafreniere, Jean-Francois Meunier, Genevieve Bibeau, Frederic Lebrun, Lu Wei Liu
  • Patent number: 7763604
    Abstract: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms by administration of the farnesylated dibenzodiazepinone compound of Formula I via continuous intravenous infusion.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: July 27, 2010
    Assignee: Thallion Pharma Ceuticals, Inc.
    Inventors: Henriette Gourdeau, Maxime Ranger, Fran├žois Berger, Bryan Simard
  • Publication number: 20090186878
    Abstract: The present invention relates to crystalline forms of ECO-4601 and the processes for providing them. The invention further relates to pharmaceutical compositions comprising the crystalline forms and to methods of use of the crystalline forms as pharmaceuticals.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 23, 2009
    Applicant: THALLION PHARMACEUTICALS INC.
    Inventors: Patrick Morris, Faustinus Yeboah, James McAlpine, Maxime Ranger, Emmanuelle Roux, Michael Harvey
  • Patent number: 7510731
    Abstract: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers. It has been determined that the inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: March 31, 2009
    Assignees: Labopharm Inc., Labopharm Europe Limited, Labopharm (Barbados) Limited
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Publication number: 20090012240
    Abstract: The instant invention provides a two-step polymerization process for preparing amphiphilic poly(N-vinyl-2-pyrrolidone), (PVP)-block-polyester copolymers and other diblock and triblock copolymers consisting of PVP as one block. The block copolymers of the invention can be used as vehicles for drug delivery.
    Type: Application
    Filed: September 16, 2008
    Publication date: January 8, 2009
    Inventors: Laibin Luo, David Lessard, Sandra Gori, Maxime Ranger, Yuan Wang, Julie Lafreniere, Jean-Francois Meunier, Genevieve Bibeau, Frederic Lebrun, Lu Wei Liu
  • Patent number: 7384935
    Abstract: This invention relates to phosphate prodrugs of a farnesylated dibenzodiazepinone, to processes of their manufacture, to pharmaceutical compositions comprising the prodrugs, and to their use in the treatment of neoplasms.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: June 10, 2008
    Assignee: Thallion Pharmaceuticals, Inc.
    Inventors: Mustapha Aouidate, James B. McAlpine, Faustinus Yeboah, Ashraf Ibrahim, Arjun H. Banskota, Maxime Ranger, Gregory L. White
  • Publication number: 20080027205
    Abstract: The instant invention provides a two-step polymerization process for preparing amphiphilic poly(N-vinyl-2-pyrrolidone), (PVP)-block-polyester copolymers and other diblock and triblock copolymers consisting of PVP as one block. The block copolymers of the invention can be used as vehicles for drug delivery.
    Type: Application
    Filed: August 6, 2007
    Publication date: January 31, 2008
    Inventors: Laibin Luo, David Lessard, Sandra Gori, Maxime Ranger, Yuan Wang, Julie Lafreniere, Jean-Francois Meunier, Genevieve Bibeau, Frederic Lebrun, Lu Liu
  • Patent number: 7262253
    Abstract: The instant invention provides a two-step polymerization process for preparing amphiphilic poly(N-vinyl-2-pyrrolidone), (PVP)-block-polyester copolymers and other diblock and triblock copolymers consisting of PVP as one block. The block copolymers of the invention can be used as vehicles for drug delivery.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: August 28, 2007
    Assignee: Labopharm, Inc.
    Inventors: Laibin Luo, David Lessard, Sandra Gori, Maxime Ranger, Yuan Wang, Julie Lafreniere, Jean-Francois Meunier, Genevieve Bibeau, Frederic Lebrun, Lu Wei Liu
  • Publication number: 20070110709
    Abstract: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers. It has been determined that the inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability.
    Type: Application
    Filed: November 10, 2006
    Publication date: May 17, 2007
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Publication number: 20070078112
    Abstract: This invention relates to phosphate prodrugs of a farnesylated dibenzodiazepinone, to processes of their manufacture, to pharmaceutical compositions comprising the prodrugs, and to their use in the treatment of neoplasms.
    Type: Application
    Filed: September 27, 2006
    Publication date: April 5, 2007
    Inventors: Mustapha Aouidate, James McAlpine, Faustinus Yeboah, Ashraf Ibrahim, Arjun Banskota, Maxime Ranger, Gregory White
  • Publication number: 20060276436
    Abstract: The invention relates to pharmaceutical formulations comprising a farnesyl dibenzodiazepinone compound, or an analog, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable surfactant and having improved chemical and biological properties. Such a formulation is a ready-to-use solution suitable for parenteral or non-parenteral administration or a bulk formulation for ex tempore preparation. The present invention also relates to therapeutic methods using the formulations, and methods for their preparation.
    Type: Application
    Filed: May 31, 2006
    Publication date: December 7, 2006
    Inventors: Maxime Ranger, Emmanuelle Roux
  • Publication number: 20060270662
    Abstract: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms by administration of the farnesylated dibenzodiazepinone compound of Formula I via continuous intravenous infusion.
    Type: Application
    Filed: May 16, 2006
    Publication date: November 30, 2006
    Inventors: Henriette Gourdeau, Maxime Ranger, Francois Berger, Bryan Simard
  • Publication number: 20050244501
    Abstract: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers. It has been determined that the inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability.
    Type: Application
    Filed: July 5, 2005
    Publication date: November 3, 2005
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Patent number: 6939564
    Abstract: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers. It has been determined that the inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: September 6, 2005
    Assignee: Labopharm, Inc.
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Publication number: 20050119404
    Abstract: The instant invention provides a two-step polymerization process for preparing amphiphilic poly(N-vinyl-2-pyrrolidone), (PVP)-block-polyester copolymers and other diblock and triblock copolymers consisting of PVP as one block. The block copolymers of the invention can be used as vehicles for drug delivery.
    Type: Application
    Filed: December 2, 2003
    Publication date: June 2, 2005
    Inventors: Laibin Luo, David Lessard, Sandra Gori, Maxime Ranger, Yuan Wang, Julie Lafreniere, Jean-Francois Meunier, Genevieve Bibeau, Frederic Lebrun, Lu Liu
  • Patent number: 6780428
    Abstract: The present invention describes the preparation of unimolecular polymeric micelles (UPM) that bear a hydrophilic shell and a potentially ionizable and relatively hydrophobic core at a determined pH value. The core becomes electrostatically charged as the pH is changed. Such micelles can be made from either biodegradable or non-biodegradable polymers. Loaded drugs can be physically retained in the micelles when the pH of the surrounding medium favors interactions with the core. Upon a change in pH, modification in the ionization state of the core will decrease the interactions between the drug and the inner core and facilitate the release of the micellar contents.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: August 24, 2004
    Assignee: Labopharm, Inc.
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Publication number: 20030059398
    Abstract: The present invention is directed toward water-soluble supramolecular self-assemblies and a process for their preparation via micellization of polyelectrolytes through the use of hydrophobic monomeric units. In this invention the polyelectrolyte segment ultimately forms the core of the supramolecular assembly whereas the shell consists of uncharged hydrophilic polymers or oligomers. It has been determined that the inclusion of the hydrophobic co-monomers to the polyelectrolyte segment forming the micelle core leads to a structure of enhanced stability.
    Type: Application
    Filed: June 8, 2001
    Publication date: March 27, 2003
    Inventors: Maxime Ranger, Jean-Christophe Leroux
  • Publication number: 20020187199
    Abstract: The present invention describes the preparation of unimolecular polymeric micelles (UPM) that bear a hydrophilic shell and a potentially ionizable and relatively hydrophobic core at a determined pH value. The core becomes electrostatically charged as the pH is changed. Such micelles can be made from either biodegradable or non-biodegradable polymers. Loaded drugs can be physically retained in the micelles when the pH of the surrounding medium favors interactions with the core. Upon a change in pH, modification in the ionization state of the core will decrease the interactions between the drug and the inner core and facilitate the release of the micellar contents.
    Type: Application
    Filed: June 8, 2001
    Publication date: December 12, 2002
    Inventors: Maxime Ranger, Jean-Christophe Leroux